{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:50:41Z","timestamp":1791535841287,"version":"4.3.4"},"reference-count":38,"publisher":"Oxford University Press (OUP)","funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031003","name":"CDC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031003","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vaccine Safety Datalink","award":["75D30122D15425"],"award-info":[{"award-number":["75D30122D15425"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Efficacy and immunogenicity of single-dose human papillomavirus (HPV) vaccination have been demonstrated among females; less is known about single-dose vaccination among males. We assessed sex differences in antibody response 12\u201348 months postvaccination among adolescents who received a single 9-valent HPV vaccine (9vHPV) dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants were recruited from an integrated healthcare delivery system in Oregon and southwest Washington. Adolescents who received a single 9vHPV dose at ages 9\u201312 years, 12\u201348 months prior to study enrollment, were identified. Serum antibody testing for each 9vHPV type (HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58) was conducted using M9ELISA. We compared antibody detection and geometric mean antibody concentrations (GMCs) among males to females.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 111 male and 96 female participants, age at vaccination (&amp;gt;95% at age 11 or 12 years) and time since vaccination (median, 20 months) were similar by sex. Among males and females, 80.2% and 89.6%, respectively, had detectable antibodies for all types, with no significant sex difference. Type-specific detection ranged from 84.7% to 99.1% for males and 91.7% to 99.0% for females, with no significant sex differences. GMCs were 31%\u201350% lower among males than females for all types (range of GMC ratios adjusted for time since vaccination, 0.50\u20130.69).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>One to 4 years after single-dose 9vHPV vaccination, males had similar detection but lower antibody concentrations than females. Because very low levels of antibody are thought to protect against HPV, the clinical significance of these sex differences is unknown.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiag476","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:20:31Z","timestamp":1789672831000},"source":"Crossref","is-referenced-by-count":0,"title":["Human Papillomavirus (HPV) Antibody Concentrations Among Male and Female Adolescents After Single-Dose 9-Valent HPV Vaccination"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2603-9494","authenticated-orcid":false,"given":"Rayleen M","family":"Lewis","sequence":"first","affiliation":[{"name":"Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5747-4643","authenticated-orcid":false,"given":"Allison L","family":"Naleway","sequence":"additional","affiliation":[{"name":"Center for Health Research, Kaiser Permanente Northwest , Portland, Oregon ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2594-1929","authenticated-orcid":false,"given":"Michelle L","family":"Henninger","sequence":"additional","affiliation":[{"name":"Center for Health Research, Kaiser Permanente Northwest , Portland, Oregon ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1151-6056","authenticated-orcid":false,"given":"Gitika","family":"Panicker","sequence":"additional","affiliation":[{"name":"Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5525-0324","authenticated-orcid":false,"given":"Bradley","family":"Crane","sequence":"additional","affiliation":[{"name":"Center for Health Research, Kaiser Permanente Northwest , Portland, Oregon ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4733-0111","authenticated-orcid":false,"given":"Ira","family":"Rajbhandari","sequence":"additional","affiliation":[{"name":"Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2349-0252","authenticated-orcid":false,"given":"Evelin","family":"Coto","sequence":"additional","affiliation":[{"name":"Center for Health Research, Kaiser Permanente Northwest , Portland, Oregon ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2925-5635","authenticated-orcid":false,"given":"Elizabeth R","family":"Unger","sequence":"additional","affiliation":[{"name":"Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2480-9520","authenticated-orcid":false,"given":"Lauri E","family":"Markowitz","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"issue":"RR-2","key":"2026100904163075400_jiag476-B1","first-page":"1","article-title":"Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Markowitz","year":"2007","journal-title":"MMWR Recomm Rep"},{"key":"2026100904163075400_jiag476-B2","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1470-2045(15)00047-9","article-title":"Efficacy of fewer than three doses of an HPV-16\/18 AS04 adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine Trial and the PATRICIA Trial","volume":"16","author":"Kreimer","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026100904163075400_jiag476-B3","doi-asserted-by":"crossref","first-page":"5413","DOI":"10.1016\/j.vaccine.2022.06.065","article-title":"Human papillomavirus vaccine effectiveness by number of doses: updated systematic review of data from national immunization programs","volume":"40","author":"Markowitz","year":"2022","journal-title":"Vaccine"},{"key":"2026100904163075400_jiag476-B4","first-page":"645","article-title":"Human papillomavirus vaccines: WHO position paper (2022 update)","volume":"97","author":"World Health Organization","year":"2022","journal-title":"Wkly Epidemiol Rec"},{"key":"2026100904163075400_jiag476-B5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.vaccine.2022.11.044","article-title":"Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination","volume":"41","author":"Joshi","year":"2023","journal-title":"Vaccine"},{"key":"2026100904163075400_jiag476-B6","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1016\/S2214-109X(23)00586-7","article-title":"Comparing one dose of HPV vaccine in girls aged 9\u201314 years in Tanzania (DoRIS) with one dose in young women aged 15\u201320 years in Kenya (KEN SHE): an immunobridging analysis of randomised controlled trials","volume":"12","author":"Baisley","year":"2024","journal-title":"Lancet Glob Health"},{"key":"2026100904163075400_jiag476-B7","doi-asserted-by":"crossref","first-page":"EVIDoa2100056","DOI":"10.1056\/EVIDoa2100056","article-title":"Efficacy of single-dose HPV vaccination among young African women","volume":"1","author":"Barnabas","year":"2022","journal-title":"NEJM Evid"},{"key":"2026100904163075400_jiag476-B8","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1038\/s41591-023-02658-0","article-title":"Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results","volume":"29","author":"Barnabas","year":"2023","journal-title":"Nat Med"},{"key":"2026100904163075400_jiag476-B9","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1056\/NEJMoa2506765","article-title":"Noninferiority of one HPV vaccine dose to two doses","volume":"393","author":"Kreimer","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100904163075400_jiag476-B10","doi-asserted-by":"crossref","first-page":"2425146","DOI":"10.1080\/21645515.2024.2425146","article-title":"Immunogenicity of the 9-valent human papillomavirus vaccine: post hoc analysis from five phase 3 studies","volume":"21","author":"Giuliano","year":"2025","journal-title":"Hum Vaccines Immunother"},{"key":"2026100904163075400_jiag476-B11","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"2026100904163075400_jiag476-B12","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2026100904163075400_jiag476-B13","volume-title":"Accessed 30 June 2025.","author":"Tasso, Inc."},{"key":"2026100904163075400_jiag476-B14","doi-asserted-by":"crossref","first-page":"113136","DOI":"10.1016\/j.jim.2021.113136","article-title":"Multiplex immunoassay to measure antibody response to nine HPV vaccine types","volume":"498","author":"Panicker","year":"2021","journal-title":"J Immunol Methods"},{"key":"2026100904163075400_jiag476-B15","doi-asserted-by":"crossref","first-page":"e2022060301","DOI":"10.1542\/peds.2022-060301","article-title":"HPV16\/18 antibody responses after a single dose of nonavalent HPV vaccine","volume":"152","author":"Zeng","year":"2023","journal-title":"Pediatrics"},{"key":"2026100904163075400_jiag476-B16","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2024"},{"key":"2026100904163075400_jiag476-B17","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: elegant graphics for data analysis","author":"Wickham","year":"2016"},{"key":"2026100904163075400_jiag476-B18","doi-asserted-by":"crossref","first-page":"106266","DOI":"10.1016\/j.cct.2021.106266","article-title":"A dose-reduction HPV vaccine immunobridging trial of two HPV vaccines among adolescent girls in Tanzania (the DoRIS trial)\u2014study protocol for a randomised controlled trial","volume":"101","author":"Baisley","year":"2021","journal-title":"Contemp Clin Trials"},{"key":"2026100904163075400_jiag476-B19","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1086\/599988","article-title":"Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials","volume":"200","author":"Schiller","year":"2012","journal-title":"J Infect Dis"},{"key":"2026100904163075400_jiag476-B20","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1186\/s12879-025-10961-z","article-title":"Immunogenicity and duration of antibodies after vaccination with a two-dose series of the nine-valent human papillomavirus vaccine among Alaska Native children: a prospective cohort study","volume":"25","author":"Steinberg","year":"2025","journal-title":"BMC Infect Dis"},{"key":"2026100904163075400_jiag476-B21","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1016\/j.vaccine.2024.04.033","article-title":"Immunogenicity of quadrivalent human papillomavirus vaccine among Alaska Native children aged 9-14 years at 5 years after vaccination","volume":"42","author":"Davis","year":"2024","journal-title":"Vaccine"},{"key":"2026100904163075400_jiag476-B22","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.vaccine.2021.02.022","article-title":"Sex difference in the immunogenicity of the quadrivalent human papilloma virus vaccine: systematic review and meta-analysis","volume":"39","author":"Aldakak","year":"2021","journal-title":"Vaccine"},{"key":"2026100904163075400_jiag476-B23","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"key":"2026100904163075400_jiag476-B24","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1146\/annurev-cellbio-100616-060718","article-title":"Sex and gender differences in the outcomes of vaccination over the life course","volume":"33","author":"Flanagan","year":"2017","journal-title":"Annu Rev Cell Dev Biol"},{"key":"2026100904163075400_jiag476-B25","first-page":"198","article-title":"The influence of sex and gender on immunity, infection and vaccination","volume":"52","author":"Ruggieri","year":"2016","journal-title":"Ann Ist Super Sanita"},{"key":"2026100904163075400_jiag476-B26","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1473-3099(10)70049-9","article-title":"The Xs and Y of immune responses to viral vaccines","volume":"10","author":"Klein","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"2026100904163075400_jiag476-B27","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"2026100904163075400_jiag476-B28","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1016\/j.vaccine.2008.09.073","article-title":"HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine","volume":"26","author":"Joura","year":"2008","journal-title":"Vaccine"},{"key":"2026100904163075400_jiag476-B29","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1016\/j.vaccine.2017.12.079","article-title":"Explanations for the high potency of HPV prophylactic vaccines","volume":"36","author":"Schiller","year":"2018","journal-title":"Vaccine"},{"key":"2026100904163075400_jiag476-B30","doi-asserted-by":"crossref","first-page":"e0255841","DOI":"10.1371\/journal.pone.0255841","article-title":"Self-collection of capillary blood using Tasso-SST devices for anti-SARS-CoV-2 IgG antibody testing","volume":"16","author":"Hendelman","year":"2021","journal-title":"PLoS One"},{"key":"2026100904163075400_jiag476-B31","doi-asserted-by":"crossref","first-page":"e002641","DOI":"10.1136\/rmdopen-2022-002641","article-title":"Remote self-collection of capillary blood using upper arm devices for autoantibody analysis in patients with immune-mediated inflammatory rheumatic diseases","volume":"8","author":"Zarbl","year":"2022","journal-title":"RMD Open"},{"key":"2026100904163075400_jiag476-B32","first-page":"825","article-title":"Patient-centric microsampling for abrocitinib pharmacokinetics: multiple-analytes assay bridging using Tasso device","volume":"16","author":"Tripathy","year":"2024","journal-title":"Bioanalysis"},{"key":"2026100904163075400_jiag476-B33","doi-asserted-by":"crossref","first-page":"e0003024","DOI":"10.1128\/spectrum.00030-24","article-title":"Evaluation of the Tasso+ blood self-collection device for quantitation of plasma cytomegalovirus (CMV) DNAemia in adult solid organ transplant recipients (SOTr)","volume":"12","author":"Phan","year":"2024","journal-title":"Microbiol Spectr"},{"key":"2026100904163075400_jiag476-B34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinbiochem.2022.06.003","article-title":"Evaluation of the Tasso-SST\u00ae capillary blood microsampling device for the measurement of endogenous uracil levels","volume":"107","author":"Menestrina Dewes","year":"2022","journal-title":"Clin Biochem"},{"key":"2026100904163075400_jiag476-B35","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1186\/s12879-022-07432-0","article-title":"Feasibility of a novel self-collection method for blood samples and its acceptability for future home-based PrEP monitoring","volume":"22","author":"Cannon","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2026100904163075400_jiag476-B36","author":"Centers for Disease Control and Prevention"},{"key":"2026100904163075400_jiag476-B37","doi-asserted-by":"crossref","first-page":"5758","DOI":"10.1016\/j.vaccine.2023.08.017","article-title":"A comparison of electronic health records and the Oregon state immunization registry for human papilloma virus vaccine delivery (2005\u20132022)","volume":"41","author":"Bumatay","year":"2023","journal-title":"Vaccine"},{"key":"2026100904163075400_jiag476-B38","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41541-024-00949-2","article-title":"WHO international standards for antibodies to HPV6 HPV11 HPV31 HPV33 HPV45 HPV52 and HPV58","volume":"9","author":"Kemp","year":"2024","journal-title":"NPJ Vaccines"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag476\/71227504\/jiag476.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag476\/71227504\/jiag476.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:16:43Z","timestamp":1791533803000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/advance-article\/doi\/10.1093\/infdis\/jiag476\/8817486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":38,"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag476","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]},"article-number":"jiag476"}}